Abstract
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Initial Data from a Phase 2, Non-Comparative Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have